tacrolimus (TACROLIMUS EXTENDED-RELEASE CAPSULES)
tacrolimus (TACROLIMUS EXTENDED-RELEASE CAPSULES) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: tacrolimus; Generic name: TACROLIMUS EXTENDED-RELEASE CAPSULES; Manufacturer: Chengdu Suncadia Medicine Co., Ltd..
| Brand name | tacrolimus |
|---|---|
| Generic name | TACROLIMUS EXTENDED-RELEASE CAPSULES |
| Manufacturer | Chengdu Suncadia Medicine Co., Ltd. |
| Used for | 1 INDICATIONS AND USAGE Tacrolimus extended-release capsules is indicated for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants in adult patients who can swallow capsules intact [see Clinical Studies ( 14.1 ), ( 14.2 )] . Pediatric use information is approved for Astellas Pharma US, Inc.'s ASTAGRAF XL (tacrolimus extended-release capsules). However, due to Astellas Pharma US, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information. Tacrolimus extended-release capsules is a calcineurin-inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in kidney transplant patients in comb |
| Dosage | 2 DOSAGE AND ADMINISTRATION Capsules must be taken whole. ( 2.1 ) Take consistently every morning at the same time on an empty stomach at least 1 hour before a meal or at least 2 hours after a meal. ( 2.1 ) Avoid eating grapefruit or drinking grapefruit juice or alcohol. ( 2.1 ) African-American patients and patients with severe hepatic impairment may require dosing adjustments. ( 2.3 ) Frequent monitoring of trough concentrations is recommended. ( 2.4 ) For complete dosing information, see Full |
| Warnings | WARNING: MALIGNANCIES AND SERIOUS INFECTIONS IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS Increased risk for developing serious infections and malignancies with tacrolimus extended-release capsulest or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] Increased mortality in female liver transplant patients with tacrolimus extended-release capsulest. Tacrolimus extended-release capsulest is not a |
| Active ingredient(s) | TACROLIMUS |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08cf2861-2483-405d-a872-a88a5c235f9a |